TransMedics Group, Inc. TMDX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 203.01M | 189.95M | 173.93M | 160.76M | 143.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 203.01M | 189.95M | 173.93M | 160.76M | 143.82M |
| Cost of Revenue | 84.35M | 76.75M | 72.77M | 67.35M | 59.25M |
| Gross Profit | 118.66M | 113.20M | 101.16M | 93.41M | 84.58M |
| SG&A Expenses | 61.33M | 57.83M | 62.99M | 51.44M | 46.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 174.86M | 166.21M | 160.64M | 139.49M | 120.52M |
| Operating Income | 28.14M | 23.74M | 13.30M | 21.27M | 23.30M |
| Income Before Tax | 24.10M | 19.41M | 8.49M | 21.63M | 23.03M |
| Income Tax Expenses | 7.03M | 4.72M | 1.17M | -83.75M | -1.29M |
| Earnings from Continuing Operations | 17.07M | 14.68M | 7.32M | 105.38M | 24.32M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.07M | 14.68M | 7.32M | 105.38M | 24.32M |
| EBIT | 28.14M | 23.74M | 13.30M | 21.27M | 23.30M |
| EBITDA | 37.98M | 33.18M | 24.46M | 28.24M | 29.75M |
| EPS Basic | 0.49 | 0.42 | 0.21 | 3.08 | 0.71 |
| Normalized Basic EPS | 0.43 | 0.35 | 0.15 | 0.40 | 0.42 |
| EPS Diluted | 0.46 | 0.41 | 0.20 | 2.58 | 0.66 |
| Normalized Diluted EPS | 0.37 | 0.30 | 0.15 | 0.33 | 0.35 |
| Average Basic Shares Outstanding | 34.69M | 34.58M | 34.38M | 34.22M | 34.11M |
| Average Diluted Shares Outstanding | 40.83M | 40.71M | 36.19M | 40.93M | 40.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |